EMA Withdrawn: Zerene (zaleplon) — Meda AB

View source ↗

Summary

EMA has withdrawn Zerene (zaleplon) from the market (Meda AB) for sleep initiation and maintenance disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sleep Initiation and Maintenance Disorders

Drugs mentioned

• Zerene (zaleplon)

Snippet

Status: Withdrawn. Therapeutic area: Sleep Initiation and Maintenance Disorders. MAH: Meda AB. Decision date: 23/08/2012